| Literature DB >> 35475154 |
Daniel D Shapiro1, John W Davis1, Wendell H Williams2, Brian F Chapin1, John F Ward1, Curtis A Pettaway1, Justin R Gregg1.
Abstract
Objective: This study aimed to identify factors associated with surgeon perception of robot-assisted radical prostatectomy (RARP) difficulty. Patients andEntities:
Keywords: prostate cancer; prostatectomy; robotic surgery
Year: 2021 PMID: 35475154 PMCID: PMC8988518 DOI: 10.1002/bco2.110
Source DB: PubMed Journal: BJUI Compass ISSN: 2688-4526
Clinical and pathologic characteristics
| Variable | Overall ( | Optimal difficulty ( | Suboptimal difficulty ( |
|
|---|---|---|---|---|
| Median age (IQR) | 68 (66.5–71) | 68 (66–71) | 68 (67–73) | 0.7 |
| Race, | 0.7 | |||
| Caucasian | 78 | 47 (81) | 31 (73.8) | |
| Black | 9 | 5 (8.6) | 4 (9.5) | |
| Hispanic | 8 | 3 (5.2) | 5 (11.9) | |
| Asian | 5 | 3 (5.2) | 2 (4.8) | |
| Median BMI (IQR) | 28.6 (25.1–31.6) | 27.3 (24.8–30.5) | 30.6 (27.5–33.5) | 0.004 |
| Smoking history | 0.9 | |||
| Never | 55 | 31 (53.5) | 24 (57.1) | |
| Prior | 39 | 23 (39.7) | 16 (38.1) | |
| Current | 6 | 4 (6.9) | 2 (4.8) | |
| Prior abdominal or pelvic surgery | 50 | 26 (44.8) | 24 (57.1) | 0.2 |
| Prior radiation | 1 | 1 (1.7) | 0 | 1 |
| Preoperative systemic therapy | 13 | 7 (12.1) | 6 (14.3) | 0.8 |
| Median prostate volume (IQR) | 37.9 (24.1–55.2) | 38.7 (26.1–62.6) | 37.3 (21.7–47.2) | 0.4 |
| Clinical T stage | 0.03 | |||
| cT1 | 48 (83) | 25 (59.5) | ||
| cT2 | 8 (14) | 12 (29) | ||
| cT3 | 2 (3) | 4 (9.5) | ||
| cT4 | 0 | 1 (2) | ||
| Median transverse pelvic diameter, cm (IQR) | 12.3 (11.6–12.8) | 12.1 (11.5–12.6) | 12.4 (11.8–12.9) | 0.2 |
| Median prostate volume:pelvic diameter, cm3/cm (IQR) | 3.17 (1.94–4.49) | 3.25 (2.13–5.97) | 2.91 (1.90–4.1) | 0.4 |
| Maximum pathologic tumor diameter, cm (IQR) | 2 (1.5–3) | 2 (1.5–2.6) | 2.5 (2–3) | 0.06 |
| Nerve spare | 0.3 | |||
| Bilateral | 60 | 35 (60.3) | 25 (59.5) | |
| Unilateral/partial | 20 | 14 (24.1) | 6 (14.3) | |
| None | 20 | 9 (15.5) | 11 (26.2) | |
| Grade group | 0.9 | |||
| 1 | 0 | 0 | 0 | |
| 2 | 44 | 27 (46.6) | 17 (40.5) | |
| 3 | 29 | 17 (29.3) | 12 (28.6) | |
| 4 | 2 | 1 (1.7) | 1 (2.4) | |
| 5 | 13 | 7 (12.1) | 6 (14.3) | |
| Absent (due to preop hormone ablation) | 12 | 6 (10.3) | 6 (14.3) | |
| Pathologic T stage | 0.2 | |||
| pT2 | 52 | 32 (55.2) | 20 (47.6) | |
| pT3a | 28 | 18 (31) | 10 (23.8) | |
| pT3b | 20 | 8 (13.8) | 12 (28.6) | |
| pT4 | 0 | 0 | 0 | |
| N+ | 20 | 9 (15.5) | 11 (26.2) | 0.2 |
| M+ | 3 | 2 (3.5) | 1 (2.4) | 0.3 |
| Extracapsular extension | 45 | 27 (46.6) | 18 (42.9) | 0.7 |
| Positive margin | 18 | 10 (17.2) | 8 (19.1) | 0.99 |
Abbreviations: BMI, body mass index; IQR, interquartile range.
Fisher's exact test or Wilcoxon rank‐sum test, when appropriate.
Surgical variables
| Variable | Overall cohort ( | Optimal difficulty ( | Suboptimal difficulty ( |
|
|---|---|---|---|---|
| Median operative time, min (IQR) | 187.5 (156.5–226) | 172.5 (149–215) | 207 (170–239) | 0.02 |
| Median insufflation pressure (IQR) | 12.1 (10.5–12.9) | 12.2 (10.4–13.1) | 12.1 (10.8–12.8) | 0.9 |
| Median estimated blood loss, ml (IQR) | 100 (100–175) | 100 (100–150) | 150 (100–250) | 0.0002 |
| Surgeon difficulty rating | ||||
| Poor | 2 | 0 | 2 (4.8) | |
| Acceptable | 13 | 0 | 13 (31) | |
| Good | 27 | 0 | 27 (64.3) | |
| Optimal | 58 | 58 (100) | 0 | |
| Intraoperative complication, | 2 | 1 (1.7) | 1 (2.4) | 0.99 |
Abbreviation: IQR, interquartile range.
Postoperative outcomes
| Variable | Overall cohort ( | Optimal difficulty ( | Suboptimal difficulty ( |
|
|---|---|---|---|---|
| Transfusion | 2 | 1 (1.7) | 1 (2.4) | 0.7 |
| 30‐day readmission | 6 | 6 (10.3) | 0 | 0.04 |
| 90‐day postoperative complication | 20 | 10 (17.3) | 10 (23.8) | 0.5 |
| Clavien–Dindo classification | 0.5 | |||
| I | 5 | 2 (3.5) | 3 (7.1) | |
| II | 7 | 3 (5.2) | 4 (9.5) | |
| IIIa | 4 | 2 (3.5) | 2 (4.8) | |
| IIIb | 3 | 3 (5.2) | 0 | |
| IVb | 1 | 0 | 1 (2.4) | |
| V | 0 | 0 | 0 |
Associations with clinical variables and surgeon‐assessed difficulty
| Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Age | 1.02 | 0.92–1.14 | 0.69 | |||
| BMI (continuous) | 1.17 | 1.06–1.30 | 0.003 | 1.14 | 1.03–1.26 | 0.01 |
| BMI (≥30 vs. <30) | 3.18 | 1.38–7.94 | 0.007 | |||
| MRI prostate volume | 0.99 | 0.97–1.01 | 0.36 | |||
| Transverse pelvic diameter | 1.12 | 0.68–1.83 | 0.66 | |||
| Prostate volume:pelvic diameter | 0.89 | 0.71–1.12 | 0.31 | |||
| Prior abdominal surgery | 1.64 | 0.74–3.66 | 0.23 | |||
| Smoking history | 0.86 | 0.39–1.92 | 0.71 | |||
| Prior systemic therapy | 1.21 | 0.38–3.92 | 0.75 | |||
| Clinical T stage | 1.64 | 1.14–2.36 | 0.008 | 1.49 | 1.03–2.15 | 0.03 |
| Nerve sparing | ||||||
| Bilateral | Ref | |||||
| Partial/unilateral | 0.6 | 0.20–1.78 | 0.4 | |||
| None | 1.71 | 0.62–4.74 | 0.3 | |||
Abbreviations: BMI, body mass index; CI, confidence interval; MRI, magnetic resonance imaging; OR, odds ratio.
FIGURE 1Violin plots of body mass index (BMI) by surgeon‐assessed robot‐assisted radical prostatectomy difficulty cohort